Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 4 Interventional

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

ClinicalTrials.gov ID: NCT05629494

Public ClinicalTrials.gov record NCT05629494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Non-steroidal Anti-inflammatory Drugs on Serum Prostate Specific Antigen Level

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.

Study identification

NCT ID
NCT05629494
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Albany Medical College
Other
Enrollment
198 participants

Conditions and interventions

Interventions

Drug · Diagnostic Test

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 26, 2022
Primary completion
Feb 28, 2026
Completion
Nov 30, 2026
Last update posted
Oct 17, 2024

2022 – 2026

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Chicago Medical Center Chicago Illinois 60637 Recruiting
Albany Medical Center Albany New York 12208 Recruiting
Penn State-Hershey Medical Center Hershey Pennsylvania 17033 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05629494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 17, 2024 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05629494 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →